Neurolief Ltd. news

Neurolief, a neurotechnology innovator, today announced new data released at the 64th Annual Scientific Meeting hosted by the American Headache Society (June 9-12th, 2022, Denver, CO).

The real-world, open-label analysis presents clinically meaningful data on the prevention of migraine, including responder rate, reduction in monthly migraine days and reduction in medication use for those with high-frequency episodic or chronic migraine. The eCOT-NS

Neurolief Ltd., a neurotechnology innovator, today announced enrollment of the first patient in its pivotal clinical study evaluating Relivion® DP for the treatment of major depressive disorder (MDD). The Relivion DP is the first non-invasi

Neurolief, an Israel-based company pioneering neuromodulation for the treatment of chronic neurological and neuropsychiatric disorders, and NeuroFront, a clinical stage biotech company focusing on innovative neuroscience therapies, jointly announced an exclusive licensing agreement for NeuroFront to develop and commercialize Relivion, non-invasive medical devices for the treatment of migraine and depression, in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea.

Neurolief Ltd., a neurotechnology innovator, today announces that it has entered into an exclusive agreement with Sawai Pharmaceutical Co., Ltd. for the development and marketing of Relivion^®, a non-inva

Neurolief, an innovator in neurotechnology, announces the company has received Food and Drug Administration (FDA) clearance for its Relivion® system. Relivion® is the first non-invasiv